The Live Biotherapeutic Product (LBP) Market is expected to grow at a 21.2 % CAGR during the forecast period for 2023-2031.
A live microbe is utilized in a Live Biotherapeutic product to treat, prevent, or cure a disease. Microorganisms that may be beneficial to health have been discovered as the human microbiome, and its relationship to human health has come to be better understood. These microorganisms have a lot of potential for use as Live Biotherapeutic products in clinical settings. Several clinical trials are being conducted to assess their potential as a treatment. LBPs are believed to have biological effects by modulating the host-microbiota rather than directly acting on known targets or distant organs, tissues, or receptors. Importantly, LBPs will have a biological effect by influencing the local ecosystem, other microorganisms, and their interactions with the host.
Throughout the forecast period, market growth is anticipated to be driven by rising research and development efforts, as well as an expanding pipeline of microbiome-targeting therapies that are anticipated to treat a wide range of serious diseases. The development of new drugs and clinical trial activities for the treatment of diseases are being aided by ongoing innovation and technological advancements.
In 2019, 4D pharma collaborated with MSD to research and develop Live Biotherapeutics for vaccines. 4D's proprietary MicroRx® platform will be combined with MSD's expertise in developing and commercializing novel vaccines. During the forecast period, significant growth opportunities are anticipated as government funding and the R&D budget for drug development both increases. Over 640 patents focused on microbiome therapeutics were approved in 2020. The complexities occur due to a lack of expertise, specialized infrastructure, the need for astronomical capital expenditures, capacity limitations, and restrictions on ensuring compliance with good manufacturing practices (GMP).
Market Segmentation:
The Live Biotherapeutic Product Market is segmented into By Product Which consists of VOWST (SER-109), REBYOTA, Visbiome, Other Pipeline Products. Whereas, By Target Disease Indication the market is segmented into Recurrent C. Difficile Infection, Irritable Bowel Syndrome (IBS), Ulcerative Colitis (UC), Antibiotic-Associated Diarrhea (AAD), Pouchitis, Hepatic Encephalopathy (HE), Graft Versus Host Disease, Necrotizing Enterocolitis, Primary Hyperoxaluria, Other Indications. The last segment is Route Of Administration which includes Oral and Rectal Therapeutics.
Regionally, North America is anticipated to experience brisk growth during the forecast period (2022-2030) as a result of rising demand and the significant COVID-19 effect. Large sums of money are given to businesses to research Live Biotherapeutic ingredients and create new products.
Competitive Landscape:
Some Of The Key Players In The Live Biotherapeutic Product (LBP) Market:
- Seres Therapeutics, Inc.
- Microbiotica
- Enterome
- Destiny Pharma plc
- Taisho Pharmaceutical Holdings
- AOBiome Therapeutics, Inc.
- Finch Therapeutics Group, Inc
- Ferring Pharmaceuticals
- Rebiotix Inc. (A Subsidiary of Ferring Pharmaceuticals)
- MaaT Pharma
- Vedanta Biosciences Inc.
- OxThera AB
- Pendulum Therapeutics
- Caelus Health
- Quorum Innovations
- Sanofi S.A
- DermBiont, Inc.
- EnteroBiotix Ltd
- YSOPIA Bioscience
- Winclove Probiotics
- TargEDys
- Evelo Biosciences, Inc.
- BiomX
- Biomica Ltd.
- Scioto Biosciences, Inc.
- Lactobio A/S
- Takeda Pharmaceutical Co. Ltd.
- Second Genome Therapeutics
- Johnson and Johnson Inc.
- Kaleido Biosciences Inc.
- OptiBiotix Health Plc
- PureTech Health Plc
- Immuron Limited
- Naked Biome
- Synthetic Biologics
- ExeGi Pharma
- Nexbiome
- Mybiotics Pharma LTD.
The Live Biotherapeutic Product (LBP) Market Report Scope:
|
Report Attribute |
Specifications |
|
Market Size Value In 2022 |
USD 432.24 Million |
|
Revenue Forecast In 2031 |
USD 3048.51 Million |
|
Growth Rate CAGR |
CAGR of 23.46 % from 2023 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Product, By Target Disease Indication, By Route Of Administration |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Seres Therapeutics, Inc., Microbiotica, Enterome, Destiny Pharma plc, Taisho Pharmaceutical Holdings, AOBiome Therapeutics, Inc., Finch Therapeutics Group, Inc, Ferring Pharmaceuticals, Rebiotix Inc. (A Subsidiary of Ferring Pharmaceuticals), MaaT Pharma, Vedanta Biosciences Inc., OxThera AB, Pendulum Therapeutics, Caelus Health, Quorum Innovations, Sanofi S.A, DermBiont, Inc., EnteroBiotix Ltd, YSOPIA Bioscience, Winclove Probiotics, TargEDys, Evelo Biosciences, Inc., BiomX, Biomica Ltd., Scioto Biosciences, Inc., Lactobio A/S, Takeda Pharmaceutical Co. Ltd., Second Genome Therapeutics, Johnson and Johnson Inc., Kaleido Biosciences Inc., OptiBiotix Health Plc, PureTech Health Plc, Immuron Limited, Naked Biome, Synthetic Biologics, ExeGi Pharma, Nexbiome, Mybiotics Pharma LTD and others. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
